Angiotensin receptor antag 
Welcome,         Profile    Billing    Logout  
 16 Companies  20 Products   20 Products   192 Diseases   481 Trials   14046 News 


«12345678910111213...103104»
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Angiotensin Receptor Antagonist/Neprilysin Inhibitor Tolerance in LVAD Recipients (Board #107; Poster Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1686;    
    Purpose The angiotensin receptor antagonist-neprilysin inhibitor (ARNi) sacubitril/valsartan is standard of care for heart failure...Several clinical, hemodynamic, and anatomical features related to a more advanced HF phenotype may be associated with ARNi intolerance and could guide patient selection and timing of initiation. Larger, prospective studies are needed to support this hypothesis and ultimately provide a rationale for routine use of ARNi in LVAD recipients.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Sacubitril-Valsartan Improves Blood Pressure Control and Contributes to Positive Left Ventricular Remodelling in Heartmate 3 LVAD Supported Patients (Board #105; Poster Hall) -  Jan 9, 2024 - Abstract #ISHLT2024ISHLT_1684;    
    There was no change in serum creatinine following initiation 88.4 ml/min/m2 to 90.7 ml/min/m2 (p=0.59).Conclusion SV is well tolerated in HM3 LVAD supported pts who were previously established on ACE inhibitor or angiotensin receptor blockers. They lead to improved BP control, and appear to be associated with positive LV remodelling, thus working synergistically with the mechanical unloading effects of an LVAD.
  • ||||||||||  Review, Journal:  Potential molecular pathways of angiotensin receptor blockers in the brain toward cognitive improvement in dementia. (Pubmed Central) -  Jan 8, 2024   
    The multivariant role of the renin-angiotensin system (RAS) in the brain offers strong evidence of a role for angiotensin receptor blockers (ARBs) in the management of memory impairment by modifying glutamate excitotoxicity, downregulating inflammatory cytokines such as interleukin (IL)-1?, IL-6 and tumor necrosis factor (TNF)?, inhibiting kynurenine aminotransferase (KAT)-II, nucleotide-binding domain, leucine-rich-containing family and pyrin-domain-containing-3 (NLRP3) inflammasomes, boosting cholinergic activity, activating peroxisome proliferator-activated receptor (PPAR)-?, countering cyclooxygenase (COX) and mitigating the hypoxic condition. The present work focuses on the intricate molecular mechanisms involved in brain-RAS, highlighting the role of ARBs, connecting links between evidence-based unexplored pathways and investigating probable biomarkers involved in dementia through supported preclinical and clinical literature.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  ARNI vs ACE inhibitor use in patients with a Left Ventricular Assist Device: A propensity score matched analysis. (Pubmed Central) -  Jan 8, 2024   
    The present work focuses on the intricate molecular mechanisms involved in brain-RAS, highlighting the role of ARBs, connecting links between evidence-based unexplored pathways and investigating probable biomarkers involved in dementia through supported preclinical and clinical literature. No abstract available
  • ||||||||||  Azilva (azilsartan) / Takeda, Kanarb (fimasartan) - Boryung Group, R / Pharm
    Angiotensin Receptor Blockers and Drug-Induced Liver Injury: A Cohort Study Using Common Data Model (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_1971;    
    In overall, the risk was significantly lower in olmesartan users compared to valsartan users (HR: 0.73 [95% confidence interval (CI): 0.55-0.96]). In patients receiving monotherapy, the risk was significantly higher in azilsartan users compared to valsartan users (HR: 6.55 [95% CI: 5.28-8.12]).
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Preventive Effect of Angiotensin II Receptor and Neprilysin Inhibitor on hepatic fibrosis in mice (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_518;    
    Although the combination of an angiotensin receptor and a neprilysin inhibitor (sacubitril/valsartan: SAC/VAL) has shown clinical efficacy in patients with heart failure, its potential effects on hepatic fibrosis have not been clarified...Moreover, VAL directly inhibited angiotensin II (AT-II)-stimulated cell proliferation and the expression of TIMP1 and CTGF through the blockade of the AT-II type 1 receptor/protein kinase C pathway. Collectively, SAC/VAL may be a novel therapeutic treatment for liver fibrosis.
  • ||||||||||  Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    RISK FACTORS FOR MACROGLOSSIA IN A NEUROCRITICAL CARE POPULATION: A CASE-CONTROL STUDY () -  Jan 4, 2024 - Abstract #SCCM2024SCCM_1397;    
    There is an association of macroglossia with longer duration of MV and sedation which may reflect a consequence of macroglossia rather than causality. A larger case-control study with matching to multiple control groups is needed to confirm these findings.
  • ||||||||||  enzyme replacement therapeutics / Washington University School of Medicine in St. Louis, UT Southwestern Medical Center, Collaborations Pharma
    Journal:  Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I. (Pubmed Central) -  Jan 4, 2024   
    Some cytokines, notably CD30 ligand, Eotaxin-2, LIX, IL-13, IL-15, GM-CSF, MCP-5, MIG, and CCL3 showed elevations in mice treated with ERT above normal or mutant levels; these elevations were reduced or absent in mice that received losartan or combination therapy. The observations suggest that losartan may impact inflammatory cascades due to MPS I and may also blunt inflammation in combination with ERT.
  • ||||||||||  Journal:  Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure. (Pubmed Central) -  Jan 4, 2024   
    Participation was not associated with a significant differential change in hospital-level risk-adjusted 30-day or 90-day all-cause readmission rate and 30-day or 90-day all-cause mortality rate. In this study, hospital participation in the BPCI Model 2 Heart Failure program was not associated with improvement in process-of-care quality measures or 30-day or 90-day risk-adjusted all-cause mortality and readmission rates.
  • ||||||||||  Filspari (sparsentan) / Travere Therap, CSL Behring
    Biomarker, Journal:  Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. (Pubmed Central) -  Jan 2, 2024   
    P3
    Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan. (Funded by Travere Therapeutics; DUPLEX ClinicalTrials.gov number, NCT03493685.).
  • ||||||||||  Journal:  Allergic manifestations in women with silicone breast implants. (Pubmed Central) -  Dec 28, 2023   
    Allergic reactions associated with SBI are not uncommon. Imbalance of circulating levels of IgE autoantibodies against GPCRs of the autonomic nervous system might play a role not only in allergic reactions, but also in other enigmatic aspects of SBII such as autoimmune dysautonomia.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal, Real-world evidence, Real-world:  Real-world analysis of integration of sacubitril/valsartan into clinical practice in Saudi Arabia. (Pubmed Central) -  Dec 26, 2023   
    Our study revealed notable disparities in the baseline characteristics of patients with HFrEF compared with those in the PARADIGM-HF trial. These findings offer valuable real-world insights into the prescription patterns and outcomes of Sac/Val in patients with HFrEF in Saudi Arabia, an aspect not previously represented in the PARADIGM-HF study.
  • ||||||||||  Journal:  Inferior vena cava collapsibility index as a predictor of hypotension after induction of general anesthesia in hypertensive patients. (Pubmed Central) -  Dec 24, 2023   
    Compared with the combination therapy of TZD and RASI, ARNI therapy causes less renal dysfunction, hyperuricemia, and hypertriglyceridemia with fewer electrolyte abnormalities and no significant difference in antihypertensive effects. An inferior vena cava collapsibility index?>?39% before anesthetic induction can be a simple noninvasive reliable predictor of hypotension after the induction of GA for hypertensive patients not treated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and undergoing noncardiac surgery.
  • ||||||||||  Journal:  Diagnosis and management of resistant hypertension. (Pubmed Central) -  Dec 23, 2023   
    Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
  • ||||||||||  TRV027 / Trevena
    Journal:  ?-arrestin pathway activation by selective ATR1 agonism promotes calcium influx in podocytes, leading to glomerular damage. (Pubmed Central) -  Dec 22, 2023   
    Recently, a novel biased AT1R agonist, TRV120027 (TRV), which selectively activates the ?-arrestin cascade and blocks the G-protein-coupled receptor pathway has been proposed as a potential blood pressure medication...TRV-activated ?-arrestin signaling in podocytes may promote TRPC6 channel-mediated Ca2+ influx, foot process effacement, and apoptosis, possibly leading to severe defects in glomerular filtration barrier integrity and kidney health. Under these circumstances, the potential therapeutic application of TRV for hypertension treatment requires further investigation to assess the balance of the benefits versus possible deleterious effects and off-target damage.
  • ||||||||||  mycophenolate mofetil / Generic mfg.
    Journal:  Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey. (Pubmed Central) -  Dec 18, 2023   
    Corticosteroids (89.1%) are universally used as first-line immunosuppression; mycophenolate mofetil is commonly used in resistant patients (49.3%)...Although most nephrologists agree on common parameters to assess clinical severity of IgAN, use of RAAS blockade, and blood pressure control, there is heterogeneity in use of other supportive therapies and initiation of immunosuppression. There is reluctance to enroll patients in clinical trials with novel treatments, principally in LMICs.
  • ||||||||||  Biomarker, Review, Journal:  Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV. (Pubmed Central) -  Dec 17, 2023   
    Statins, angiotensin-receptor blockers, and anti-hyperglycemic agents as well as optimal adherence, exercise, and intermittent fasting among others have had beneficial impact on markers of immune activation and levels of inflammatory biomarkers. However, several investigations had inconclusive outcomes so further studies with larger sample sizes are warranted.
  • ||||||||||  Inpefa (sotagliflozin) / Lexicon Pharma, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Review, Journal, Adverse events:  Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure. (Pubmed Central) -  Dec 17, 2023   
    In CHF or diabetes-patients, DDI were reportedwith interleukin-17-inhibitors, linezolid, lithium, tacrolimus, valproate, angiotensin-receptor-neprilysin-inhibitorsand intravenous iron. Guidelines recommend treatmentwith SGLT2-I for CHF but no data on AE during long-term therapy and only littleinformation on DDI are available, which stresses the need for further research.Evidence-based recommendations for ketoacidosis-prevention are desirable.
  • ||||||||||  Review, Journal:  Patient Centered Heart Failure Therapy. (Pubmed Central) -  Dec 17, 2023   
    Outpatient addition of an angiotensin receptor-neprilysin inhibitor to a beta-adrenergic receptor blocker or vice versa completes the quadruple therapy scheme. By focusing on decongestion and matching intervention to patients' profile, the present therapeutic sequence allows rapid implementation of quadruple therapy at fully recommended doses.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  Does sacubitril/valsartan work in children with heart failure?-a pilot study. (Pubmed Central) -  Dec 14, 2023   
    Sacubitril/valsartan may be effective in children with HF, but its safety and outcomes may differ depending on the etiology and anatomy of HF. Early post-operative congenital heart disease patients had less tolerance, more hypotension but better recovery and outcomes, while mid- and late- post-operative congenital heart disease patients and cardiomyopathy patients had less side effects but poorer clinical outcomes.